Full interview: Dr. Ronald Petersen
Eli Lilly last week announced the results of a Phase 3 trial on its experimental drug called Donanemab. The drug attacks the amyloid proteins in the brain that lead to a buildup of plaque between neurons that weakens the ability of the neurons to communicate. The growth of these plaques along with tau protein strands leads to Alzheimer?s disease and dementia that robs a person of their memory, and eventually their bodily functions leading to death. Tim Blotz spoke with Dr. Ronald Petersen about the drug.
Top Videos
Full interview: Dr. Ronald Petersen
MN weather: Seasonable & Sunny Saturday, Hot & Humid Sunday
MSP Airport offers sensory-friendly space to support Special Olympians
Minnesota Wild's Bill Guerin named NHL GM of the Year
Community members react to Blue Line Extension update
Pride festival focuses on fundraising efforts
Powerful earthquakes rock Venezuela, search for survivors ongoing
Reaction to Rep. Emmer's town hall comments about Somali-Americans
Iran strikes ship in Strait of Hormuz: What we know
Minneapolis couple goes viral for homemade cookies
Minneapolis council approves 6-month data center pause
Gold medalist Suni Lee visits Special Olympics athletes
Enough Said: Timberwolves and Wild leadership, Naz Reid traded and the World Cup
Heritage Park apartments neglect despite public funding
The Great Midwest Rib Fest is this weekend
Debunking viral sunscreen misinformation
Preserving Minnesota's lesbian history
St. Peter police officer shot during standoff released from the hospital
Trump emphasizes religious freedom at faith coalition
Henderson Sauerkraut Days kicks off this weekend
Bloody Red Shrimp found in Lake Superior
Remembering Jodi Huisentruit 31 years after her disappearance
Trump: 'I would be the greatest communist in history'
Inver Grove Heights residents decry proposed data center
Metro Transit blue line construction: What to expect
